THE PHARMACOKINETICS OF MELPHALAN IN PATIENTS WITH MULTIPLE-MYELOMA - AN INTRAVENOUS ORAL STUDY USING A CONVENTIONAL DOSE REGIMEN

被引：36
|
作者：
WOODHOUSE, KW [1 ]
HAMILTON, P [1 ]
LENNARD, A [1 ]
RAWLINS, MD [1 ]
机构：
[1] ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1983年 / 24卷 / 02期
关键词：
D O I：
10.1007/BF00613833
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：283 / 285
页数：3
相关论文
共 50 条
  • [21] HIGH-DOSE MELPHALAN (HDM) IN MULTIPLE-MYELOMA
    SELBY, P
    POWLES, R
    ROBINSON, B
    VINCENT, M
    MCELWAIN, TJ
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 247 - 247
  • [22] ORAL DOSAGE OF MELPHALAN AND RESPONSE TO TREATMENT IN MULTIPLE-MYELOMA
    FERNBERG, JO
    JOHANSSON, B
    LEWENSOHN, R
    MELLSTEDT, H
    EUROPEAN JOURNAL OF CANCER, 1990, 26 (03) : 393 - 396
  • [23] HIGH-DOSE INTRAVENOUS MELPHALAN IN A PATIENT WITH MULTIPLE-MYELOMA AND OLIGURIC RENAL-FAILURE
    PECHERSTORFER, M
    ZIMMERROTH, I
    WEIDINGER, S
    IRSIGLER, K
    HALBMAYER, WM
    ULRICH, W
    FISCHER, M
    BAUMGARTNER, G
    CLINICAL INVESTIGATOR, 1994, 72 (07): : 522 - 525
  • [24] INTERMITTENT LOW-DOSE MELPHALAN AND PREDNISONE IN MULTIPLE-MYELOMA
    YALON, M
    LEVO, Y
    MANY, A
    RAMOT, B
    HAREFUAH, 1977, 92 (07) : 296 - 299
  • [25] A COMPARISON OF ORAL MELPHALAN, CCNU AND BCNU IN THE TREATMENT OF MULTIPLE-MYELOMA
    CORNWELL, GG
    PAJAK, TF
    MCINTYRE, OR
    KOCHWA, S
    SCHWARTZ, JM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 537 - 537
  • [26] Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
    Nath, Christa E.
    Shaw, Peter J.
    Trotman, Judith
    Zeng, Lihua
    Duffull, Stephen B.
    Hegarty, Gareth
    McLachlan, Andrew J.
    Gurney, Howard
    Kerridge, Ian
    Kwan, Yiu Lam
    Presgrave, Peter
    Tiley, Campbell
    Joshua, Douglas
    Earl, John
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 484 - 497
  • [27] BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Popat, R.
    Oakervee, H.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Harding, S.
    Mead, G.
    Cavenagh, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 365 - 366
  • [28] ORAL VERSUS INTRAVENOUS MELPHALAN AND PREDNISONE TREATMENT IN MULTIPLE-MYELOMA STAGE-II - A RANDOMIZED STUDY FROM THE MYELOMA GROUP OF CENTRAL SWEDEN
    OSTERBORG, A
    AHRE, A
    BJORKHOLM, M
    BJOREMAN, M
    BRENNING, G
    GAHRTON, G
    GRIMFORS, G
    GYLLENHAMMAR, H
    HAST, R
    JOHANSSON, B
    JULIUSSON, G
    JARNMARK, M
    KILLANDER, A
    KIMBY, E
    LERNER, R
    NILSSON, B
    PAUL, C
    SIMONSSON, B
    STALFELT, AM
    SMEDMYR, B
    SVEDMYR, E
    UDEN, AM
    WADMAN, B
    OSBY, E
    MELLSTEDT, H
    ACTA ONCOLOGICA, 1990, 29 (06) : 727 - 731
  • [29] HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Cangini, D.
    Cerchione, C.
    Giannini, M. B.
    Di Battista, V.
    Frabetti, F.
    Petracci, E.
    Ronconi, S.
    Martinelli, G.
    HAEMATOLOGICA, 2019, 104 : 163 - 163
  • [30] PK-Directed Intravenous Busulfan In Combination With High-Dose Melphalan and Bortezomib As Conditioning Regimen For Patients With Multiple Myeloma
    Barta, Stefan K.
    Mazumder, Amitabha
    Carter, Jason
    Almanzar, Lawrence
    Elkind, Richard
    Battini, Ramakrishna
    Derman, Olga
    Kornblum, Noah
    Xue, Xiaonan
    Verma, Amit
    Braunschweig, Ira
    BLOOD, 2013, 122 (21)
12345